HCV Advocate Logo
Contact Us Site Map  
For living Positivley. Being Well
About Hepatitis
Hepatitis C
Hepatitis B Overview
Fact Sheets
News Updates
Community & Support
Resource Library
About Hcsp
Back to News Review

Bookmark and Share


AASLD 2011 Liver Meeting
HBV Coverage

by Christine M. Kukka

Hepatitis B experts from around the world, meeting at the 61st annual meeting of the American Association for the Study of Liver Diseases, shared the latest in hepatitis B treatment and research.  Here are some of the highlights. 


PDFDownload pdf


Antiviral Treatment Updates

Tenofovir and entecavir updates

Side effects from antivirals examined

Interferon and antiviral treatment combinations

Preventing mother-to-child infection

Screening and treatment programs are inadequate


Potential new treatment:
Phase I and II studies show that REP 9AC appears to prevent the release of hepatitis B surface antigen (HBsAg) from HBV-infected liver cells.  (HBsAg is vital to reproduction of the virus.)  REP 9AC rapidly clears HBsAg from the bloodstream and enables patients to achieve low or undetectable viral load in a short period of time.

In this study, eight HBsAg-positive patients with high viral load (and significant liver fibrosis) were treated with REP9 AC injections and monitored weekly.  Seven of the eight patients either cleared or had very low levels of HBsAg, and surface antibodies were detected in all patients. 

Clearance of HBsAg occurred as early as 7 days and no later than 32 weeks.  Three patients were treated for 20 and 27 weeks.  All three have continued to have low- to undetectable viral load up to 18 months after stopping treatment.

“These results suggest that REP 9AC may become an important new tool in the treatment of chronic hepatitis B,” researchers reported.

  • 235.  REP 9AC: A potent HBsAg release inhibitor that elicits durable immunological control of chronic HBV infection. 

HBV Genotype A is most common in the U.S.:
A surveillance study, spearheaded by the U.S. Centers for Disease Control and Prevention, tested 204 blood samples from people experiencing acute hepatitis B (indicating new infections) to see which strain or genotype was most prevalent in the U.S.

Samples were collected from Connecticut, Oregon, Colorado, Minnesota, New York state, and New York City between 2007 and 2010.

They found that 78% had genotype A, 2% had genotype B, 5% had genotype C, 14% had genotype D and 1% had genotype H.  No differences were found in genotype by age, sex or year of report.

Genotype A was more prevalent among whites (82%) and African-Americans (89%), while non-genotype A cases were more prevalent among Asian-Americans, who were either genotype B or D, and Hispanics who were genotype C, D, or H. 

  • 1116.  Genotypic Characterization of Acute Hepatitis B Virus Cases from Selected Surveillance Sites, United States, 2007-2010. 

Patients under age 40 found at high risk of fibrosis and cirrhosis:
Historically, most treatment and research has focused on older patients infected with the hepatitis B virus (HBV), who have higher rates of cirrhosis during their 50s and 60s.  However, a Canadian team conducted liver biopsies on 262 hepatitis B patients and compared the liver health of those under and over age 40.

They found that 33 (13%) patients had advanced fibrosis—of them 14 (42%) were under age 40.

These younger patients were more likely to be HBeAg-positive, and have genotype C.

“Our data indicate that advanced fibrosis among young patients who underwent liver biopsy is common,” they reported.  Young cirrhotic patients tended to have lower viral loads, but more liver inflammation revealed by biopsy.  Ultrasounds would have missed cirrhosis in 64% of the younger patients, underscoring the value of using biopsies to determine liver health.

  • 505.  Factors associated with advanced hepatic fibrosis in young patients with chronic hepatitis B infection.


Antiviral Treatment Updates

Do antivirals really induce HBeAg seroconversion?:
Despite reports of successful HBeAg seroconversions (loss of HBeAg and production of “e” antibodies) in clinical trials, the conversion rate in real life medical practices appears much lower, according to a California study.

Clinical trials report a seroconversion rate of 15-22% from antiviral treatment, but researchers followed 333 HBeAg-positive patients treated with antivirals at three clinics and found that only 9.6% lost HBeAg loss and 8.2% achieved HBeAg seroconversion after one year of treatment.

Most of the patients in the study were male and Asian-American.  The type of antiviral used did not make much difference in the seroconversion rate.  “HBeAg seroconversion rates in clinical settings are lower than those reported in registration trials, especially those with lower ALT and higher HBV DNA levels,” they noted.  “HBeAg-positive patients should be counseled about the possibility that long-term treatment may be required to achieve HBeAg seroconversion.”

  • 1441.  Low Incidence of Hepatitis B e Antigen (HBeAg) Seroconversion with Oral Monotherapy in Chronic Hepatitis B (CHB) Treatment-Naïve Patients at Year 1 in Clinical Practice.

Effective antiviral treatment works within 3 to 6 months:
Selecting the right antiviral, and making sure it is effective within three to six months of launching treatment, is essential to long-term antiviral treatment in patients with cirrhosis, according to a Chinese study.

Researchers followed 443 patients, mostly male, and found that patients whose HBV DNA was quickly lowered to near undetectable levels within six months fared much better than those who took up to 12 months to experience a drop in their viral load.

Early viral suppression by (antivirals) essentially dramatically reduces the risk of developing drug resistance in patients during the next 4 to 10 years of treatment.

  • 1405.  Early Viral Suppression with Nucleos(t)ides Therapy Reduces Drug-resistance Development in Cirrhotic Hepatitis B Patients. 

Long-term antiviral treatment no cure-all for cirrhosis or liver cancer:
Researchers followed 121 patients treated for three years with antivirals to see how successful the treatment was in staving off cirrhosis or liver cancer over a six-year period.  Most were treated with either lamivudine or another antiviral, and many developed antiviral resistance.

Most patients did well, but 10 of 74 patients developed cirrhosis and one patient developed liver cancer.

  • 498.  Long-term outcome of liver disease in patients with HBV-related Chronic Hepatitis under protracted nucleos(t)ide analogs. 

Can people ever stop taking antivirals?:
A Taiwanese study followed 79 patients for more than a year after they stopped entecavir treatment.  They found 28.5% of the patients experienced a relapse—with a resurgence in HBV DNA—after stopping treatment. 

  • 1379.  Off therapy durability in chronic hepatitis B e antigen negative patients treated with entecavir.

A German study followed 32 HBeAg-negative patients who stopped taking antivirals (most male, average age 47) after seven years of successful treatment.  They reported that 23 of the patients relapsed and were put back on antivirals.  Nine patients did well off antivirals—most of them had very low levels of HBsAg (below 1,000 IU/ml) when they stopped treatment, and four of them lost HBsAg within 14 months of stopping treatment.

  • 1417.  Stopping long-term nucleos(t)ide analogue therapy before HBsAg loss or seroconversion in HBeAg negative CHB patients: experience from five referral centers in Germany


Tenofovir and entecavir updates

Long-term tenofovir reverses fibrosis and cirrhosis among Asian Patients:
Asian patients who took the antiviral tenofovir (Viread) over five years had dramatic declines in HBV DNA (viral load) and improvements in fibrosis and cirrhosis—and they experienced no antiviral resistance despite the lengthy treatment period.

Liver biopsies before and after five years of treatment found 95% of patients with fibrosis had improvements (or no worsening) in liver health, 86% of cirrhotic patients no longer had cirrhosis and 96% of patients achieved undetectable viral load (less than 400 copies/mL). 

Surprisingly, no Asian patients lost the hepatitis B surface antigen (HBsAg) during the five-year treatment period.  None of the patients had kidney problems or appeared to lose bone mineral density despite the long duration of antiviral treatment.

  • 1376.  Five years of Treatment with Tenofovir DF for Chronic Hepatitis B Infection in Asian Patients is Associated with Sustained Viral Suppression and Significant Regression of Histological Fibrosis and Cirrhosis.

  • 238.  No Detectable Resistance to Tenofovir Disoproxil Fumarate (TDF) Following up to 240 Weeks of Treatment in Patients with HBeAg+ and HBeAg- Chronic Hepatitis B Virus Infection. 

Entecavir proves effective:
Several studies involving entecavir treatment showed the antiviral to be effective, although it is less effective in patients who have already developed resistance to lamivudine and adefovir, and it has a slightly higher rate of resistance than tenofovir.  In the Korean study cited below, 72 patients (mostly male, average age 49, never before treated) received entecavir for three years.  Only one developed resistance.

Of the 45 HBeAg-positive and 27 HBeAg-negative patients, 51.1% and 85.2% responded respectively with lowered viral load and healthier livers.  About 25% of HBeAg-positive patients seroconverted.

  • 1409.  48 weeks, Profound Suppression Correlates with Greater Sustained Response in Treatment-Naive Chronic Hepatitis B Patients Treated with Entecavir. 


Side effects from antivirals examined

Tenofovir and entecavir: No threat to kidneys?:
Increasingly, researchers are reporting that some antivirals cause kidney damage (and harming renal function) and are finding side effects.  They followed 212 patients treated with tenofovir and 79 treated with entecavir (most were male, half were African-American, and 24% were Asian-American.)

They monitored their renal function at the start of treatment, and six and 12 months later and found no deterioration in renal function in the tenofovir-treated patients, and only a small impact on renal function in the entecavir-treated group. 

  • 496 A single centre, large 'real-life' cohort treated with tenofovir versus entecavir: no deterioration in renal function. 

Other doctors find kidney damage from antivirals:
Increasingly, doctors are finding that long-term use of antivirals causes kidney damage, as evidence by reduced renal function.  French researchers followed 220 antiviral-treated patients (mostly male, average age 47), including 30% with extensive fibrosis or cirrhosis, who were treated for an average 4.6 years.  Researchers found above-average rates of renal impairment among the antiviral-treated patients.

  • 1444.  Renal impairment under nucleotide analogues in a monocentric cohort of patients with chronic HBV monoinfection. 

Tenofovir and entecavir don’t lower vitamin D levels:
Researchers are also worried about the impact of antivirals on vitamin D levels, which are essential to maintain healthy bone density.  A British study of 212 patients treated with tenofovir and 79 treated with entecavir found that while hepatitis B in itself reduces vitamin D levels in patients, “tenofovir and entecavir treatment had no significant effect on vitamin D levels after 12 months of treatment.”

  • 509.  No effect of Tenofovir or Entecavir on Vitamin D levels in Chronic Hepatitis B mono-infected patients.  Single centre 'real life' cohort experience. 

Weakened bones found in tenofovir- and adefovir-treated patients:
A National Institutes of Health study found phosphate wasting nephropathy in between 10 and 15% of patients treated for two years with either tenofovir or adefovir.

They followed 51 patients treated for an average 6.3 with the two antivirals, and reported that 14% developed phosphate wasting nephropathy, which can lead to bone softening and degeneration, after an average of three years.

The problem is, “partially reversible with change to other antivirals,” researchers wrote, “but may result in significant osteomalacia (bone softening) if not recognized and managed promptly.  Routine monitoring of serum phosphate, creatinine, uric acid and urinalysis is prudent during long-term adefovir and tenofovir therapy.”

  • 237 Phosphate Wasting Nephropathy in Patients with Chronic Hepatitis B treated with Long-term Adefovir or Tenofovir. 

A similar study in Italy looked at the bone mineral density of 124 patients treated with lamivudine and/or tenofovir.  They found 77% of the patients had no signs of bone weakening, 8% actually had improved bone density, but 15% had suffered bone loss. 

  • 1385.  The course of bone mineral density in patients with chronic hepatitis B long-term treated with nucleos(t)ide analogs: a longitudinal cohort study. 


Interferon and antiviral treatment combinations

Historically, researchers have had little success treating patients with a combination of antivirals and pegylated interferon.  However, new studies unveiled at the conference show that first lowering a patient’s viral load with antivirals, and then adding interferon to activate the immune system may be a more successful strategy.

40% of patients treated with sequential antiviral and interferon treatment lose HBsAg:
Researchers explored the impact of adding up to 96 weeks of pegylated interferon to ongoing antiviral treatment in 10 patients who had undetectable viral load, as a result of antiviral treatment, when the interferon treatment began.

The antivirals used included lamivudine, adefovir, entecavir, or a combination of them.  Ultimately 40% of the patients lost HBsAg and one patient developed surface antibodies.

  • 1382.  Add -on of peg interferon to a stable nucleoside regimen led to loss of HBsAg in chronic hepatitis HBe Ag negative patients. 

Hard-to-treat HBeAg-positive patients also appear to benefit from antiviral-interferon treatment:
Researchers compared one group of HBeAg-positive patients who used only entecavir to a second group who added interferon to their ongoing entecavir regimen.  In the second group, there was an eight-week overlap where patients received both interferon and entecavir, after which patients were treated with only interferon.

Seven of 53 interferon-treated patients (13%) had HBsAg clearance (compared to 0% in the entecavir-only group).  Three of the 53 (6%) cleared the infection, losing HBsAg and developing surface antibodies.

Patients with HBsAg levels less than 3,000 IU/mL and who were HBeAg-negative at the start of treatment had the highest chance of clearing HBsAg.

  • 1373.  Patients with HBeAg-positive chronic hepatitis B (CHB) with a maintained virological response to entecavir achieved HBsAg clearance when switched to peginterferon alfa-2a therapy (the OSST study). 

Another study compared 218 HBeAg-positive patients who received just pegylated interferon against patients who received varying sequences of entecavir and interferon.  The groups were then followed for six months after treatment ended.  At the end of the follow-up:

The interferon-only group had a HBeAg seroconversion rate of 30.6%, higher than the 24.7% and 26% rates scored by the two groups that did sequential interferon and entecavir treatment.  However, 2.4% of the interferon group lost HBsAg, compared to 6.8% rate in the group receiving interferon and then entecavir.

  • 1386.  A novel combination regimen of peginterferon alfa-2a and entecavir results in sustained post-treatment HBsAg clearance in HBeAg-positive chronic hepatitis B (CHB). 

Another study focusing on HBeAg-patients followed 266 patients treated with interferon for one year and 91 treated with only entecavir.  Those receiving interferon had higher rates of HBeAg seroconversion, and 30 (8%) of patients even cleared HBsAg, most of whom received interferon. 

“This shows that (interferon) remains an important treatment option in HBeAg-positive patients to achieve serological response,” they wrote.

  • 1398.  Peginterferon is superior to prolonged entecavir therapy for serological response in HBeAg-positive chronic hepatitis B. 

A Vietnamese research team tried switching both HBeAg-positive and –negative patients who had been taking antivirals to interferon.  Of the 13 HBeAg-positive patients, 7 (54%) responded and 6 had HBeAg seroconversion and 3 cleared HBsAg.  The remaining did not respond and were placed back on antivirals.

Of the 10 HBeAg-negative patients, 50% responded and 4 even cleared HBsAg.

  • 1403.  Peginterferon alfa-2a monotherapy as a strategy for achieving sustained response in patients switched from long-term nucleos(t)ide analog therapy: The results of 1 year follow up. 


Preventing mother-to-child infection

Tenofovir may be best antiviral to lower viral load in pregnant women:
An Australian study suggests that tenofovir may be the best antiviral to lower a pregnant woman’s viral load to prevent mother-to-child transmission of HBV infection.

Starting at week 32 of pregnancy, they treated 8 women with tenofovir and 44 women with lamivudine, and compared their viral loads prior to treatment and at delivery, and then tested the babies at age 9 months.

Women receiving tenofovir had much lower viral loads when treatment stopped, and none of the babies in either group contracted hepatitis B (compared to two in a control group where there was no antiviral treatment.)

“Lamivudine is effective but failed to achieve adequate viral suppression in 20% of women treated,” researchers noted.  Because researchers believe some babies become infected while in utero, tenofovir may be the more effective drug because of its more effective reduction in viral load in the mother during pregnancy.

  • 1117.  Nucleot(s)ide analogues to prevent perinatal transmission of HBV: Lamivudine is effective but tenofovir may be better. 

Another study suggests that waiting until the third trimester of pregnancy to start antiviral treatment is just as effective as starting it during the second trimester in pregnant women with high viral loads.

  • 236.  Lamivudine Use in the 2nd or 3rd Trimester of Pregnancy has Similar Efficacy in Preventing Vertical Transmission (VT) of Chronic Hepatitis B (CHB) in Highly Viremic Mothers.

Study finds need for clear practice guidelines for treating HBV-infected pregnant women:
A study that followed how doctors in a NYC public health clinic treated HBV-infected pregnant women found that doctors are slowly changing their practices and are increasingly using antivirals to prevent mother-to-child infection.

However, currently there are no clear practice guidelines for managing these patients, and the U.S. Food and Drug Administration has not yet approved antiviral use in pregnant women.

Researchers wrote, “Guidelines for the management of pregnant women chronically infected with HBV should be standardized to establish ongoing monitoring for HBV-related complications, provide HBV-specific treatment and decrease the risk of immunoprophylaxis failure in their infants.”

  • 1104.  Changing Trends in the Evaluation and Management of Pregnant Women Chronically Infected with Hepatitis B Virus (HBV) in a New York City Public Health Network, 2004 – 2010. 

Telbivudine also appears effective in preventing infection:
A Chinese study followed 36 pregnant women with high viral load, who were treated with telbivudine prior to delivery.  None of the children developed hepatitis B, in contrast an untreated control group had a perinatal infection rate of 17.6%.

  • 1383.  Efficacy and Safety of Telbivudine in Pregnant Chronic Hepatitis B Patients. 


Screening and treatment programs are inadequate

Studies find poor screening for hepatitis B among Asian-Americans:
In several studies, U.S. researchers continued to identify a lack of accurate information among health care providers and Asian-Americans.

One study found many with the infection had no idea how they acquired it, and listed food, street vendors, and a dirty wound as possible causes.  Many were not vaccinated, and many were unaware that parents or siblings were infected and that they were at high risk of hepatitis B.

NYC screening program uncovers need for screening and treatment:
A NYC-based screening initiative targeting foreign-born Korean and Chinese communities found a chronic hepatitis B infection rate of 9%.  “This establishes the importance of ethnic urban screening programs that partner with public and community providers to ensure detection of disease and linkage to care,” researchers wrote.

  • 475.  Hepatitis Outreach Network (HONE): HBV and HCV Screening of Ethnic Urban Populations of New York City with Linkage to Care. 

Despite guidelines mandating HBV screening for Asian-Americans, only half are tested

Researchers scoured the records of more than 300,000 adult Asian-American patients enrolled in the Northern California Kaiser Permanente Medical Care Program to see what percentage of this group, which is at high risk of HBV infection, were screened for the infection, and what care those with diagnosed chronic hepatitis B received.

Only 52% of Asian adults were screened, according to their medical records.  Screening rates ranged from 47% (Filipino) to more than 60% (Chinese and Vietnamese).

Women were more likely screened than men, likely a result of prenatal care.  Older adults, over age 60, had the lowest screening rates.

Chronic hepatitis B rates among patients were 4.1% for Filipinos, 6% for Korean, 9.1% for Chinese, and 11.8% for Vietnamese. 

All (11,128) Asian patients with known chronic infections were studied.  Rates of ever receiving antiviral therapy ranged from 12% (Filipino) to 28% (Korean).  While over 42% of Chinese, Korean, and Vietnamese patients had HBV DNA testing done in the year 2009, only 29% of Filipino patients had such testing.

Liver imaging rates for those at risk for cirrhosis and liver cancer ranged from 41% (Filipino) to 63% (Korean), and alpha fetoprotein testing for liver cancer ranged from 38% (Filipino) to 54% (Chinese).

“Improvements in hepatitis B screening coverage and disease management are crucial to assuring health equity among Asian-American ethnic groups,” researchers wrote.  “Programs that are tailored to patient ethnicity and associated cultural factors may be essential to success.”

  • 1094.  Variations in chronic hepatitis B screening and management among Asian-American ethnic groups in a California managed care program. 

Community outreach programs vital:
Nationwide, health educators are trying a series of community outreach programs in order reach Asian-Americans who do not regularly interact with health care providers due to lack of insurance and cultural differences.

One project in the Dallas-Fort Worth area offered free testing and education to the Vietnamese-American community, and then invited participants back three weeks later to review test results and get free immunization where needed.

Most were born in Vietnam, 35% were college-educated, only 32% had health insurance, and 70% had heard about hepatitis B but only 37% had ever been tested.

Test results showed 61% of attendees were immune (had either been immunized or had a resolved infection), 24% had not been exposed to the infection and required immunization, and 15% were infected with HBV.

Community outreach programs are an effective tool to increase HBV awareness and link patients to appropriate care, researchers noted.

  • 1109.  Community Outreach and Education Programs are Effective at Improving Hepatitis B Knowledge Among Asian/Pacific Islander Adults. 

Primary care physicians need more education about hepatitis B:
As found in other studies, primary care physicians often fail to screen, immunize and treat people for hepatitis B.  Multiple education programs and interventions are needed to improve HBV knowledge and screening practices among these physicians.

  • 1114.  HBV Screening and Prevention: Evaluating Barriers for Primary Care Physicians. 

  • 1118.  Lack of Screening and Linkage to Care for Hepatitis B in the Primary Care Setting in the United States.

Lack of health insurance hinders access to care:
A large study of Asian-Americans in Los Angeles found that a lack of medical insurance played a role in preventing 40% of those with hepatitis B from receiving treatment and adequate follow-up care. 

  • 1107.  Demographical and Serological Characteristics of Asian-Americans with Chronic Hepatitis B Diagnosed at Community Screenings. 

About Hepatitis | News Updates | Community & Support Resource Library | About HCSP | Contact Us | Site Map | Home

Hepatitis C Support Project
(C) 2011. Hepatitis C Support Project

Fact Sheets
Fact Sheets
Fact Sheets